Alzheimer's - Did You Offer a Placebo Drug to People at High Risk?

In 2013, we began immunizing people who were cognitively unimpaired against Alzheimer's disease with an anti-amyloid immunotherapy. And continued this treatment in the study for roughly eight years. It wrapped up in 2022. The top line results were that we didn't achieve our primary objectives of showing delayed worsening of memory and other thinking ability on two key outcomes. But there are some tantalizing clues in favor of drug versus placebo, but these do not reach statistical significance.